NCT00085553View on ClinicalTrials.gov

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 20, 2004

Primary Completion Date

May 7, 2008

Study Completion Date

May 16, 2018

Conditions
Solid Neoplasm
Interventions
DRUG

Erlotinib Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Tipifarnib

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00085553 - Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter